Drug intelligence / Profile preview

AK0406

Development stage: Phase 1
Lead developer: Ark Biosciences
Administration: Subcutaneous, Inhalation

Overview

**AK0406** is an investigational therapeutic developed by Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) for the treatment of influenza. It targets infectious diseases, specifically human influenza, with its global highest R&D status reported as preclinical. Limited public details are available on its modality, mechanism of action, or specific indications beyond influenza, though it appears in ArkBio's respiratory disease pipeline alongside other antivirals like ziresovir.[3][13][14]

Beyond the preview

Go deeper on AK0406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK0406.

Explore the full profile